[go: up one dir, main page]

BG62611B1 - Съединения на пиролидинилхидроксамовата киселина и метод затяхното получаване - Google Patents

Съединения на пиролидинилхидроксамовата киселина и метод затяхното получаване Download PDF

Info

Publication number
BG62611B1
BG62611B1 BG101896A BG10189697A BG62611B1 BG 62611 B1 BG62611 B1 BG 62611B1 BG 101896 A BG101896 A BG 101896A BG 10189697 A BG10189697 A BG 10189697A BG 62611 B1 BG62611 B1 BG 62611B1
Authority
BG
Bulgaria
Prior art keywords
compound
acetamide
hydroxy
formula
phenylethyl
Prior art date
Application number
BG101896A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG101896A (en
Inventor
Fumitaka Ito
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of BG101896A publication Critical patent/BG101896A/xx
Publication of BG62611B1 publication Critical patent/BG62611B1/bg

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
BG101896A 1995-03-31 1997-09-17 Съединения на пиролидинилхидроксамовата киселина и метод затяхното получаване BG62611B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP9500631 1995-03-31
PCT/JP1996/000820 WO1996030339A1 (en) 1995-03-31 1996-03-28 Pyrrolidinyl hydroxamic acid compounds and their production process

Publications (2)

Publication Number Publication Date
BG101896A BG101896A (en) 1999-01-29
BG62611B1 true BG62611B1 (bg) 2000-03-31

Family

ID=14125824

Family Applications (1)

Application Number Title Priority Date Filing Date
BG101896A BG62611B1 (bg) 1995-03-31 1997-09-17 Съединения на пиролидинилхидроксамовата киселина и метод затяхното получаване

Country Status (35)

Country Link
US (2) US5952369A (is)
EP (1) EP0817772B1 (is)
JP (1) JP3035356B2 (is)
KR (1) KR100258657B1 (is)
AP (1) AP625A (is)
AR (1) AR002729A1 (is)
AT (1) ATE231840T1 (is)
AU (1) AU693336B2 (is)
BG (1) BG62611B1 (is)
BR (1) BR9607750A (is)
CA (1) CA2213815C (is)
CZ (1) CZ306497A3 (is)
DE (1) DE69626009T2 (is)
DK (1) DK0817772T3 (is)
ES (1) ES2188743T3 (is)
HR (1) HRP960141A2 (is)
HU (1) HUP9900767A3 (is)
IL (2) IL117440A0 (is)
IS (1) IS4547A (is)
LV (1) LV11971B (is)
MA (1) MA23832A1 (is)
NO (1) NO974513L (is)
NZ (1) NZ304113A (is)
OA (1) OA10518A (is)
PE (1) PE43397A1 (is)
PL (1) PL322652A1 (is)
RU (1) RU2144917C1 (is)
SI (1) SI9620039A (is)
SK (1) SK129897A3 (is)
TN (1) TNSN96045A1 (is)
TR (1) TR199701082T1 (is)
TW (1) TW408111B (is)
WO (1) WO1996030339A1 (is)
YU (1) YU18696A (is)
ZA (1) ZA962476B (is)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9701042A (es) * 1996-02-07 1998-05-31 Pfizer Compuestos del acido hidroxamico.
TNSN97092A1 (ar) 1996-09-18 1999-12-31 Agouron Pharma مثبطات انزيم بروتيني فلزي وتركيبات صيدلانية تحتوي على تلك المثبتطات واستخدامها الصيدلاني وطرق ومركبات وسيطة مفيدة لتحضير التركيبات المذكورة.
WO1998024431A1 (en) * 1996-12-02 1998-06-11 Kyorin Pharmaceutical Co., Ltd. Novel n-substituted pyrrolidine derivatives and process for preparing the same
CA2276074A1 (en) * 1997-01-10 1998-07-16 Merck & Co., Inc. Efficient synthesis of a chiral mediator
EP0982297A3 (en) * 1998-08-24 2001-08-01 Pfizer Products Inc. Process for the preparation of hydroxy-pyrrolidinyl hydroxamic acid derivatives being opioid kappa receptor agonists
KR100295740B1 (ko) * 1998-09-17 2001-11-05 박영구 N-치환된-하이드록시고리화알킬아민유도체의제조방법
US6444829B1 (en) * 2000-07-19 2002-09-03 Hoffmann-La Roche Inc. Pyrrolidine compounds
JP2005508851A (ja) 2001-04-30 2005-04-07 ファイザー・プロダクツ・インク カッパーアゴニストとして有用なヒドロキシピロリジニルエチルアミン化合物の調製方法
US7091357B2 (en) * 2001-12-26 2006-08-15 University Of Kentucky Research Foundation Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies
GB0202873D0 (en) * 2002-02-07 2002-03-27 Novartis Ag Organic compounds
AU2003269399A1 (en) * 2002-11-01 2004-05-25 Pfizer Products Inc. Process for the preparation of pyrrolidinyl ethylamine compounds via a copper-mediated aryl amination
EP1615883A1 (en) * 2003-04-14 2006-01-18 Warner-Lambert Company Process for preparing 5-(4-fluorophenyl)-1-[2-((2r,4r)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide
UA89035C2 (ru) * 2003-12-03 2009-12-25 Лео Фарма А/С Эфиры гидроксамовых кислот и их фармацевтическое применение
GB0821010D0 (en) * 2008-11-17 2008-12-24 Univ Warwick Plant development control composition
JP6254075B2 (ja) 2011-05-16 2017-12-27 バイオノミックス リミテッド カリウムチャネル遮断剤としてのアミン誘導体
KR101773331B1 (ko) * 2012-03-05 2017-08-31 닥터 레디스 레보러터리즈 리미티드 카파 오피오이드 수용체(κor) 작용제인 치환된 헤테로시클릭 아세트아미드
GB201210395D0 (en) * 2012-06-11 2012-07-25 Syngenta Participations Ag Crop enhancement compositions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3268539A (en) * 1963-05-20 1966-08-23 Universal Oil Prod Co Tertiary-aminoalkyl derivatives of diaryl substituted acetohydroxamic acid esters

Also Published As

Publication number Publication date
CA2213815A1 (en) 1996-10-03
US6110947A (en) 2000-08-29
KR100258657B1 (ko) 2000-07-01
AU693336B2 (en) 1998-06-25
ES2188743T3 (es) 2003-07-01
BR9607750A (pt) 1998-06-30
PE43397A1 (es) 1997-10-13
IL129479A0 (en) 2000-02-29
LV11971A (lv) 1998-02-20
KR19980703476A (ko) 1998-11-05
AR002729A1 (es) 1998-04-29
ATE231840T1 (de) 2003-02-15
EP0817772A1 (en) 1998-01-14
PL322652A1 (en) 1998-02-16
HUP9900767A2 (hu) 1999-07-28
AP9600791A0 (en) 1996-04-30
EP0817772B1 (en) 2003-01-29
ZA962476B (en) 1997-09-29
TNSN96045A1 (fr) 2005-03-15
WO1996030339A1 (en) 1996-10-03
DK0817772T3 (da) 2003-05-19
CZ306497A3 (cs) 1998-07-15
YU18696A (sh) 1999-06-15
IS4547A (is) 1997-08-19
IL117440A0 (en) 1996-07-23
OA10518A (en) 2002-04-22
HUP9900767A3 (en) 2001-01-29
DE69626009T2 (de) 2003-08-14
BG101896A (en) 1999-01-29
SK129897A3 (en) 1998-11-04
JP3035356B2 (ja) 2000-04-24
MA23832A1 (fr) 1996-10-01
AP625A (en) 1997-12-24
NO974513D0 (no) 1997-09-29
SI9620039A (sl) 1998-08-31
HRP960141A2 (en) 1997-10-31
LV11971B (en) 1998-06-20
JPH11501048A (ja) 1999-01-26
DE69626009D1 (de) 2003-03-06
MX9707454A (es) 1998-07-31
TW408111B (en) 2000-10-11
CA2213815C (en) 2001-12-18
TR199701082T1 (xx) 1998-02-21
NO974513L (no) 1997-09-29
NZ304113A (en) 1999-01-28
US5952369A (en) 1999-09-14
RU2144917C1 (ru) 2000-01-27
AU5121196A (en) 1996-10-16

Similar Documents

Publication Publication Date Title
BG62611B1 (bg) Съединения на пиролидинилхидроксамовата киселина и метод затяхното получаване
US20030153507A1 (en) HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
KR100229117B1 (ko) 피페리딘 유도체
JP2000504677A (ja) 5ht7レセプター・アンタゴニスト用のスルホンアミド誘導体
CZ4994A3 (en) Pyrrolidine derivatives, process of their preparation and medicaments in which said derivatives are comprised
JP4221447B1 (ja) ムスカリン様受容体アンタゴニストとしてのカルボキサミド誘導体
US20030144270A1 (en) NK1 antagonists
JP2935899B2 (ja) ▲下k▼レセプターアゴニストとしてのn−(2−(ピロリジニル−1)−1−フェニルエチル)アセトアミド
Liu et al. Divergent syntheses of L-733, 060 and CP-122721 from functionalized pieridinones made by one-pot tandem cyclization
JP3245578B2 (ja) ピロリジニルヒドロキサム酸化合物の製造方法
JP3190588B2 (ja) ヒドロキサム酸化合物
CA2603030C (en) Benzyloxypropylamine derivative
US5716936A (en) Pyrrolidine derivatives for the treatment of cholecystokinine and gastrine-related disorders
MXPA97007454A (en) Hydroxamic pirrolidinil acid compounds and their product procedure
KR20250020444A (ko) 아제티딘 화합물, 그의 약학 조성물, 제조 방법 및 중추신경계 질환 치료에서의 그의 용도
JPH1112250A (ja) カッパアゴニストとしてのヒドラジド化合物